Navigation Links
Oncobiologics, Inc. Announces a Collaboration Agreement with XOMA Corporation to Utilize XOMA's Fully Human Antibody Libraries for Their Discovery Platform
Date:7/30/2012

CRANBURY, N.J., July 30, 2012 /PRNewswire/ -- Oncobiologics, Inc. announced today a collaboration agreement with XOMA Corporation to develop novel biotherapeutics based on engineering single-chain variable fragments (scFv) into a bi-specific antibody scaffold. Through the partnership, Oncobiologics will utilize XOMA's ADAPT™ fully human antibody technology platform as a key component of its drug discovery program. Oncobiologics has selected clinically validated targets that will be used in the development of its bi-specific antibody platform targeting three therapeutic areas: Oncology, Immuno-Oncology and Immunology.

Under the agreement, Oncobiologics will gain access to XOMA's highly diverse library of scFv antibodies and associated patent estate, and will utilize XOMA's know-how and proven software tools as it advances its own candidates for treating cancer and immune diseases. Financial terms were not disclosed.

Pankaj Mohan, Ph.D., Founder & CEO of Oncobiologics, commented, "We are very excited to partner with XOMA to advance our discovery pipeline. Their proven technology represents an important asset to support our strategy to deliver improved efficacy and safety in our drug candidates. Access to this technology is a key differentiator for the bi-specific mAb candidates in our pipeline and we believe this creates significant value for our programs."

Joseph Bertino, M.D., Chief Scientific Officer of the Cancer Institute of New Jersey and Head of Oncobiologics' Scientific Advisory Board, added, "Fully human single chain antibodies in a bi-specific format offer promising opportunities for a new class of biotherapeutics designed to enhance efficacy and safety. Bringing together these capabilities with Oncobiologics' platform creates an exciting pathway for enhancing oncology treatment."

About Oncobiologics, Inc.

Headquartered in Cranbury, N.J., Oncobiologics is a biopharmaceutical company developing a pipeline of nex
'/>"/>

SOURCE Oncobiologics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. MiMedx Group Announces Record Second Quarter Results
2. Verenium Announces EPA Authorization To Market Its Next-Generation Enzyme Breaker For Hydraulic Fracturing
3. PhoenixSongs Biologicals, Inc. Announces Enhanced Neural Lineage-specific Cell Culture Media Products Release
4. Leading India-USA based CRO Announces Data Management/EDC, Medical Writing Milestone
5. IDEXX Laboratories Announces Second Quarter Results
6. Amgen Announces 2012 Third Quarter Dividend
7. Merck Company Foundation Announces HIV Care Collaborative with Atlanta, Houston and Philadelphia Health Departments
8. Critical Process Filtration Announces New Website and Expanded Literature Library
9. Sangamo BioSciences Announces Second Quarter 2012 Conference Call and Webcast
10. Neogen Corporation Announces Year-End Results Conference Call
11. Convergence Pharmaceuticals Announces Successful Completion of Phase I for CNV2197944 and Plans Phase II Studies in Neuropathic Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... THOUSAND OAKS, Calif. , Feb. 26, 2015 /PRNewswire/ ... has achieved Gold Partner status in Oracle PartnerNetwork. In ... Oracle for its commitment to establish Oracle-related knowledge in ... addressing the challenges of joint customers. Originally ... allows researchers to rapidly zoom in and out of ...
(Date:2/26/2015)... -- Epic Sciences announced today that President and CEO ... Annual Cowen and Company Health Care Conference on Wednesday, March ... Floor. The conference will be held at the Boston ... is developing diagnostic tests of high clinical utility to ... occur during the course of cancer treatments. From a ...
(Date:2/26/2015)... , Feb. 26, 2015  Spark Therapeutics (NASDAQ: ... team will participate in the Cowen and Company Health ... a.m., Eastern, at the Boston Marriott Copley Place. ... Therapeutics presentation from the Cowen conference, please visit the ... of the Spark Therapeutics website at www.sparktx.com .  ...
(Date:2/26/2015)... February 26, 2015 On Wednesday, February ... building a nationwide Clostridium difficile (C. diff) awareness movement, ... burden study by the Centers for Disease Control & ... almost half a million infections among Americans in a ... homes. , The study also estimates that 29,000 ...
Breaking Biology Technology:Ceres Becomes Oracle PartnerNetwork Gold Level Partner 2Ceres Becomes Oracle PartnerNetwork Gold Level Partner 3Ceres Becomes Oracle PartnerNetwork Gold Level Partner 4Epic Sciences to Present at 35th Annual Cowen and Company Health Care Conference 2Spark Therapeutics to Participate in the 35th Annual Cowen and Company Health Care Conference 2Peggy Lillis Foundation Lauds CDC's New, More Comprehensive Study on the Burden of C. difficile Infections in the United States 2Peggy Lillis Foundation Lauds CDC's New, More Comprehensive Study on the Burden of C. difficile Infections in the United States 3Peggy Lillis Foundation Lauds CDC's New, More Comprehensive Study on the Burden of C. difficile Infections in the United States 4
... Monday, January 28, The Royal,Marsden Hospital (Sutton, ... Arc Therapy (VMAT)* treatment in the world ... treatment, the hospital,used its existing Elekta Synergy(R) ... system., (Logo: http://www.newscom.com/cgi-bin/prnh/20020318/ELEKTALOGO ), ...
... Caliper Life,Sciences, Inc. (Nasdaq: CALP ) ... 2008 Small and Mid Cap Growth Conference in ... at 4:40 p.m. EST. Kevin,Hrusovsky, President and CEO ... the,company,s business. The live webcast can be accessed ...
... Germany and MINNEAPOLIS, Minnesota, February 11, Bayer HealthCare ... Minneapolis, MN, (Nasdaq: POSS ), announced today ... pursuant to which,MEDRAD will acquire Possis Medical in ... or a total equity value of approximately US-Dollar ...
Cached Biology Technology:Elekta Announces First Volumetric Modulated Arc Therapy Cancer Treatment at Royal Marsden Hospital 2Bayer HealthCare Affiliate MEDRAD and Possis Medical Sign Definitive Merger Agreement 2Bayer HealthCare Affiliate MEDRAD and Possis Medical Sign Definitive Merger Agreement 3Bayer HealthCare Affiliate MEDRAD and Possis Medical Sign Definitive Merger Agreement 4Bayer HealthCare Affiliate MEDRAD and Possis Medical Sign Definitive Merger Agreement 5Bayer HealthCare Affiliate MEDRAD and Possis Medical Sign Definitive Merger Agreement 6
(Date:2/9/2015)... 9, 2015  Lintec of America recently announced an ... nanotube (CNT) macrostructures, including sheets, yarns and ribbons, developed ... Leveraging the vast industrial resources of the global ... , Lintec of America is forming the Nano-Science and ... , focusing on scaling up the manufacturing and commercialization ...
(Date:2/5/2015)... 2015   Epic Sciences , a precision diagnostics company ... Murali Prahalad , Ph.D., president and CEO, is scheduled ... (PMWC) 2015: Silicon Valley, which is taking place at the ... on January 26-28, 2015. Dr. Prahalad ... Biomarkers." Last year, Epic Sciences was a finalist in the ...
(Date:2/5/2015)... , January 28, 2015 New ... Size And Segment Forecasts To 2020 has Been Added ... camera market is expected to reach USD 5.10 billion ... View Research, Inc. IR cameras help identify the site ... expected to witness surging demand in medical imaging applications. ...
Breaking Biology News(10 mins):Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3
... old, have been ill, or suffered an injury, you,ve watched ... slight or gradualis about as common to the human condition ... little about what causes skeletal muscles to atrophy. They know ... and parsing the key actors from the poseurs is tricky. ...
... A broken chromosome is like an unmoored beansprout circling in ... with broken chromosomes, the cell will be killed and so ... Often, it finds a workable substitute: another nearby chromosome. When ... a similar process to exchange genetic material, you,ve got a ...
... found a way to replace up to 50 per cent ... Warwick chemists have taken out much of the cocoa butter ... with tiny droplets of juice measuring under 30 microns in ... dark and white chocolate using what is known as a ...
Cached Biology News:Researchers identify key culprit causing muscle atrophy 2Researchers identify key culprit causing muscle atrophy 3Chromosomal translocations point the way toward personalized cancer care 2Chromosomal translocations point the way toward personalized cancer care 3Fruity science halves fat in chocolate 2
... and efficient method for purification of DNA fragments ... fragments selectively absorbed in the spin column after ... room temperature for PCR product with equal volume ... DNA can be purified with a single prep ...
When added to either StemSep CD4+ or CD8+ T Cell Enrichment cocktails, human HLA-DR TAC is designed to deplete human HLA-DR from samples to isolate resting CD4+ or CD8+ T cells....
Fujifilm BAS-1800II provides the ideal configuration for a low-cost imager that requires only a small amount of space in the laboratory. The small imager for accurate high-throughput screening...
Request Info...
Biology Products: